Corbus Pharmaceuticals reported a $37.8 million net loss for the third quarter and highlighted progress in its oncology and obesity programs. The company has begun a registrational Phase 3 trial of its cancer drug sutantatug envedotin and reported positive early results for its oral obesity drug CRB-913.
Key details
-
Cancer drug enters a registrational trial: Corbus began dosing patients in September in TEMPO-1, a randomized study of sutantatug envedotin, also known as CRB-701, in patients with advanced oropharyngeal squamous cell carcinoma (OPSCC) whose disease has been treated previously. The FDA cleared the study in July.
-
TEMPO-1 will compare the drug with three existing treatments: The 250-patient study is testing sutantatug envedotin against doctors’ choice of capecitabine, cetuximab or docetaxel. Tumor response is the main measure intended to support a potential accelerated approval; overall survival is the main measure for a possible full approval.
-
The drug has FDA Fast Track designation for OPSCC and cervical cancer. Corbus licenses sutantatug envedotin from CSPC Megalith Biopharmaceutical. The company also plans to report data in the first quarter of 2027 from a study combining the drug with Keytruda in first-line OPSCC.
-
CRB-913 produced weight loss in an early-stage study: In the 16-week CANYON-1 trial, 254 adults with obesity and without diabetes received one of three daily doses or placebo. After 12 weeks of treatment, all three doses showed statistically significant and clinically meaningful weight loss. The 60-mg dose produced mean weight loss of 5%; the company said weight loss had not plateaued at any dose by that point.
-
Corbus described CRB-913’s safety and tolerability as favorable, citing fewer and milder gastrointestinal side effects than those reported for marketed oral GLP-1 drugs. That comparison is based on separate studies, not a direct head-to-head trial. The company plans to present additional CANYON-1 data on November 15 and discuss the drug’s development plan with the FDA. It is also evaluating whether CRB-913 could be combined with GLP-1 therapy.
-
Management change: Leonardo Viana Nicacio, M.D., was appointed chief medical officer in August. He has more than 20 years of pharmaceutical-industry experience, including oncology drug development and work on the antibody-drug conjugates PADCEV and TIVDAK.
-
Quarterly results: Corbus reported a net loss of approximately $37.8 million, or $1.81 per basic and diluted share, for the three months ended September 30, 2026.
What changes for investors
TEMPO-1 moves sutantatug envedotin into late-stage, registration-oriented testing, while CRB-913 remains at an early clinical stage following its Phase 1b results. Neither program’s reported progress represents an approval: the cancer drug is being tested against existing treatments, and CRB-913’s weight-loss and safety findings will require further evaluation.